The effect of prior docetaxel (DOC) treatment on efficacy and safety of apalutamide (APA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN.

The effect of prior docetaxel (DOC) treatment on efficacy and safety of apalutamide (APA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN. Meeting Abstract

sustainable development goals

SDG 03: Good Health and Well-being

publication date

February 20, 2022

webpage

Web of Science

published in

JOURNAL OF CLINICAL ONCOLOGY Journal

volume

40

issue

6